Related references
Note: Only part of the references are listed.A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate
My Wintzell et al.
CANCER BIOLOGY & THERAPY (2012)
The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells
Medhi Wangpaichitr et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Thermal Stability of siRNA Modulates Aptamer-conjugated siRNA Inhibition
Alexey Berezhnoy et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Retinoblastoma Treatment: Utilization of the Glycolytic Inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to Target the Chemoresistant Hypoxic Regions in LHBETATAG Retinal Tumors
Yolanda Pina et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism
Xing-Jie Liang et al.
MOLECULAR CANCER RESEARCH (2008)
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
N. Tajeddine et al.
ONCOGENE (2008)
Targeting hypoxia, a novel treatment for advanced retinoblastoma
Hinda Boutrid et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose
Johnathan C. Maher et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis
Zejia Yang et al.
CLINICAL CANCER RESEARCH (2006)
Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt
R. B. Robey et al.
ONCOGENE (2006)
Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria
S. P. Mathupala et al.
ONCOGENE (2006)
Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18 F]fluorothymidine positron emission tomography:: The effect of cisplatin on a fibrosarcoma tumor model in vivo
J Leyton et al.
CANCER RESEARCH (2005)
Multifaceted roles of glycolytic enzymes
JW Kim et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions
JC Maher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak
N Majewski et al.
MOLECULAR CELL (2004)
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo
G Maschek et al.
CANCER RESEARCH (2004)
Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C)
HP Liu et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis
JG Pastorino et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
